Overview

A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.

Eligibility

Inclusion Criteria:

• 1\. Male or female participants aged 18-75 years (inclusive) at the time of informed consent;
• 2\. Must have been born in Japan, and their biological parents and grandparents must have been of Japanese origin;
• 3\. Office mean sitting SBP≥ 140 mmHg and \< 170 mmHg at screening

Exclusion Criteria:

• 1\. Participants with secondary hypertension, including but not limited to the following conditions: obstructive sleep apnea;
• 2\. History of orthostatic hypotension
• 3\. Current or history of intolerance to AECI, ARB, ARNI or direct renin inhibitor
• 4\. With diseases that require treatment with renin-angiotensin-aldosterone system (RAAS) inhibitors other than hypertension at screening;
• 5\. Presence of serious active and uncontrolled physical conditions or medical history, which may be in a dangerous state during the use of the study drug, or interfere with the interpretation of efficacy and safety data of this study, as judged by the investigator prior to randomization